Mizuho Maintains Outperform on Biogen, Raises Price Target to $241
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.